EHA 2022: Investigational Epcoritamab Shows Promise in Relapsed/Refractory Large B-Cell Lymphoma
Phase II dose-expansion findings demonstrate high overall and complete response rates with good tolerability
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.